title: Cardiovascular risk in type 2 diabetics and pharmacological regulation of mealtime glucose excursions.
abstract: In type 2 diabetic patients mealtime glucose fluctuations are important determinants of overall glucose control and overall risk of diabetes cardiovascular complications. In fact, acute elevation of plasma glucose concentrations trigger an array of tissue response that may contribute to development of such vascular complications since it may result in a thrombophilic condition, causes endothelial dysfunction (possibly through a reduction of nitric oxide availability) and is responsible for non-enzymatic glycation and production of free- radicals with ensuing oxidative stress. To keep post-prandial glucose with narrow range, metiglinide analogues drugs have been developed. In particular, repaglinide and nateglinide seem the most useful ones. In fact, both drugs improve 1(st) phase insulin release but they do not affect the total daily amount of insulin released by the pancreas. Due to the mechanism of action and to pharmacokinetic properties, repaglinide and nateglinide allow diabetic patients to get a more tight metabolic glucose control with a contemporary reduction in the cases of severe hypoglycaemia. In conclusions, repaglinide and nateglinide are new and powerful pharmacological tools not only for achieving a better metabolic glucose control but also for preventing the development of diabetes-related cardiovascular complications.
authors.affiliation: Dipartimento di Geriatria e Malattie del Metabolismo, II Università degli Studi di Napoli, Napoli. guiseppe.paolisso@unina2.it
authors.forename: G
authors.initials: G
authors.lastname: Paolisso
authors.forename: M R
authors.initials: MR
authors.lastname: Rizzo
authors.forename: M
authors.initials: M
authors.lastname: Barbieri
authors.forename: D
authors.initials: D
authors.lastname: Manzella
authors.forename: E
authors.initials: E
authors.lastname: Ragno
authors.forename: D
authors.initials: D
authors.lastname: Maugeri
mesh_terms: D000284:Administration, Oral; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000453:epidemiology*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003925:Diabetic Angiopathies / Q000453:epidemiology*; D004435:Eating; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D019518:Postprandial Period; D012307:Risk Factors
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents